Total Payments
$2,118
2024 Payments
$260.04
Companies
15
Transactions
43
Medicare Patients
697
Medicare Billing
$86,779
Payment Breakdown by Category
Food & Beverage$2,118 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,118 | 43 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $571.71 | 7 | $0 (2020) |
| Novo Nordisk Inc | $353.55 | 4 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $215.35 | 3 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $208.70 | 2 | $0 (2019) |
| Astellas Pharma US Inc | $176.33 | 3 | $0 (2024) |
| Guard Medical Inc. | $138.73 | 1 | $0 (2024) |
| AbbVie Inc. | $121.18 | 10 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $104.79 | 1 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $61.89 | 1 | $0 (2018) |
| Allergan Inc. | $44.14 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $260.04 | 3 | Guard Medical Inc. ($138.73) |
| 2023 | $82.86 | 3 | Astellas Pharma US Inc ($55.02) |
| 2021 | $209.08 | 14 | AbbVie Inc. ($121.18) |
| 2020 | $90.33 | 2 | PFIZER INC. ($79.14) |
| 2019 | $949.14 | 10 | PFIZER INC. ($290.01) |
| 2018 | $206.13 | 4 | PFIZER INC. ($132.57) |
| 2017 | $320.84 | 7 | SANOFI-AVENTIS U.S. LLC ($104.79) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/06/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $102.84 | General |
| Category: Biological | ||||||
| 05/23/2024 | Guard Medical Inc. | NPSEAL LARGE (Device) | Food and Beverage | In-kind items and services | $138.73 | General |
| Category: NEGATIVE PRESSURE WOUND THERAPY | ||||||
| 02/27/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Biological | ||||||
| 11/30/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Cardiology | ||||||
| 09/07/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $55.02 | General |
| Category: Biological | ||||||
| 01/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Cardio-renal | ||||||
| 12/21/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/11/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: NEUROSCIENCE | ||||||
| 09/14/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $46.70 | General |
| Category: Gastroenterology | ||||||
| 08/31/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.29 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $5.83 | General |
| Category: NEUROSCIENCE | ||||||
| 04/30/2021 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Central Nervous System | ||||||
| 04/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.19 | General |
| Category: NEUROSCIENCE | ||||||
| 03/29/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $9.36 | General |
| Category: NEUROSCIENCE | ||||||
| 03/24/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $25.73 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $10.20 | General |
| Category: NEUROSCIENCE | ||||||
| 02/19/2021 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Central Nervous System | ||||||
| 02/02/2021 | Lilly USA, LLC | EMGALITY (Drug), TRULICITY | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Neuroscience | ||||||
| 01/26/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: NEUROSCIENCE | ||||||
| 10/28/2020 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: Central Nervous System | ||||||
| 02/20/2020 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $79.14 | General |
| Category: GASTROINTESTINAL | ||||||
| 12/03/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $123.92 | General |
| Category: GASTROINTESTINAL | ||||||
| 10/30/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $104.35 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/22/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $62.03 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 155 | 401 | $45,369 | $23,113 |
| 2022 | 5 | 155 | 423 | $37,919 | $23,620 |
| 2021 | 5 | 181 | 462 | $36,755 | $22,326 |
| 2020 | 5 | 206 | 418 | $29,440 | $17,720 |
Total Patients
697
Total Services
1,704
Medicare Billing
$86,779
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 69 | 273 | $38,705 | $19,031 | 49.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 22 | 22 | $2,150 | $1,582 | 73.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 14 | $1,975 | $1,481 | 75.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $1,100 | $633.29 | 57.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 17 | 28 | $704.00 | $229.01 | 32.5% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 14 | 42 | $735.00 | $156.66 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 70 | 299 | $33,525 | $20,769 | 62.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 27 | 27 | $2,025 | $1,851 | 91.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 27 | 27 | $675.00 | $661.50 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 28 | $959.00 | $192.95 | 20.1% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2022 | 14 | 42 | $735.00 | $146.00 | 19.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 77 | 306 | $31,745 | $19,201 | 60.5% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 31 | 31 | $2,320 | $2,023 | 87.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 34 | 34 | $850.00 | $537.88 | 63.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 21 | 33 | $825.00 | $300.72 | 36.5% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2021 | 18 | 58 | $1,015 | $262.91 | 25.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 75 | 257 | $23,480 | $13,877 | 59.1% |
| 90653 | Vaccine for influenza for injection into muscle | Office | 2020 | 45 | 45 | $3,375 | $2,679 | 79.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 46 | 46 | $1,150 | $728.18 | 63.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 22 | 28 | $700.00 | $243.59 | 34.8% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2020 | 18 | 42 | $735.00 | $191.52 | 26.1% |
About Dr. Michael Watson, M.D
Dr. Michael Watson, M.D is a General Practice healthcare provider based in Farmerville, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1245429471.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Watson, M.D has received a total of $2,118 in payments from pharmaceutical and medical device companies, with $260.04 received in 2024. These payments were reported across 43 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,118).
As a Medicare-enrolled provider, Watson has provided services to 697 Medicare beneficiaries, totaling 1,704 services with total Medicare billing of $86,779. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Farmerville, LA
- Active Since 10/24/2007
- Last Updated 10/24/2007
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245429471
Products in Payments
- Ozempic (Drug) $281.78
- EUCRISA (Drug) $237.70
- FARXIGA (Drug) $208.70
- COLOGUARD (Device) $203.06
- Veozah (Drug) $176.33
- NPSEAL LARGE (Device) $138.73
- LYRICA (Drug) $130.95
- TRULANCE (Drug) $115.35
- PRALUENT (Drug) $104.79
- XIFAXAN (Drug) $100.00
- UBRELVY (Drug) $98.57
- Tresiba (Drug) $71.77
- JARDIANCE (Drug) $61.89
- Trulance (Drug) $41.82
- AJOVY (Biological) $37.69
- VRAYLAR (Drug) $34.28
- BYSTOLIC (Drug) $21.11
- EMGALITY (Drug) $14.70
- Kerendia (Drug) $14.04
- Repatha (Biological) $13.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.